Vitalgen completed the enrollment in the Phase I/II clinical trial of the world's first BCD gene therapy
On September 21, 2023, the surgical administration of all subjects was successfully completed in the Phase I/II clinical trial of VGR-R01, marking another critical step toward the marketing of this world-first therapeutic product.